China (Mainland)
dabigatran etexilate CAS NO.211915-06-9
- Min.Order: 1 Kilogram
- Payment Terms: L/C,D/A,D/P,T/T,MoneyGram,Other
- Product Details
Keywords
- dabigatran etexilate
- 211915-06-9
- C34H41N7O5
Quick Details
- ProName: dabigatran etexilate
- CasNo: 211915-06-9
- Molecular Formula: C34H41N7O5
- Appearance: White crystalline powder
- Application: Pharmaceuticals
- DeliveryTime: 2-3day
- PackAge: 25KG/Cardboard bucket or as required
- Port: shanghai or other
- ProductionCapacity: 5 Metric Ton/Month
- Purity: 99（%）
- Storage: cool and dry place
- Transportation: by sea or by air
- LimitNum: 1 Kilogram
Superiority
1 all ip developed as a service by tianma’s chemists, under a customer cda or msa, is the property of the customer. under customer cda or msa, all of the tianma chemists’ ip development service is belong to customers.
2 duty of confidentiality has been written in employment contract. and every employee should agree and sign it.
3 customer and tianma’s ip are protected by both side’s national law and company agreements.
electronic security access and information dissemination are controlled strictly.
1 secure vpn tunnels for email transfers confidential info to customers.
2 tianma central document server (cds) which can assigned security access, control the access of project specific information.
3 notebooks, mor’s and others are collected in archived room and be monitored under strict access.
4 only the basic information( need to know level) of the project details shared by related working group.
tianma has additional proactive employee training which emphasize about the law and risk of persecution and conviction:
1 regular retraining of tianma staff on ip protection and need for security.
2 inviting local police to introduce the latest criminal convictions of ip theft in china.
3 explanation of china patent law and customer cda‘s.
| Dabigatran etexilate Basic information |
| Product Name: | Dabigatran etexilate |
| Synonyms: | Dabigatran Free Base;BIBR-1048 (Dabigatran);Dabigatran Etexilatr;BIBR-1048(Dabigatran etexilate);N-[2-[4-[N-(Hexyloxycarbonyl)aMidino]phenylaMinoMethyl]-1-Methyl-1H-benziMidazol-5-ylcarbonyl]-N-(2-;BIBR 1048;(E)-ethyl 3-(2-((4-(N'-(hexyloxycarbonyl)carbamimidoyl)phenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate;BIBR-1048, >=99% |
| CAS: | 211915-06-9 |
| MF: | C34H41N7O5 |
| MW: | 627.74 |
| EINECS: | 606-722-8 |
| Product Categories: | -;Pharmaceutical intermediate;API;Dabigatran etexilate;Other APIs |
| Mol File: | 211915-06-9.mol |
|
|
|
| Dabigatran etexilate Chemical Properties |
| Melting point | 128-129° |
| Safety Information |
| Dabigatran etexilate Usage And Synthesis |
| Indications and Usage | Dabigatran is the newest generation of oral anticoagulant drugs – direct thrombin inhibitors (DTIs), belonging to non-peptide thrombin inhibitors and instead specifically and selectively blocks the thrombin activity (free or bound) to prevent coagulation. Dabigatran targets the preventative and clinical treatment needs of acute and chronic thromboembolic disease. |
| Mechanisms of Action | It achieves anticoagulant effects through specific and selective inhibition of blood enzymes (free or bound). After oral ingestion and absorption through the digestive system, Dabigatran turns into Dabiga groups that have the direct anticoagulant abilities. By binding to thrombin in fibrin specific binding sites, Dabigatran stops fibrinogen from cleaving into fibrin, thus interrupting the blood clotting network and consequently thrombosis. Dabiga groups can also dissociate from the fibrin-thrombin coagulate and have an anticoagulating effect. Different from vitamin K antagonists, which affect different coagulants, Dabigatran can provide effective, predictable and stable anticoagulant effects. It will also have minimal reactions to other drugs or food, and does not require frequent monitoring or dosage adjustment. |
| Clinical Research | Compared to the control group treated with Warfarin, Dabigatran can significantly decrease the risk of stroke and embolic disease (including hemorrhagic stroke), greatly reduce the occurrence of bleeding (including fatal bleeding and intracranial hemorrhage), and greatly lower vascular mortality rate. Dabigatran provides effective and stable anticoagulant effects and does not require constant monitoring of anticoagulant functions or dosage adjustments. |
| Warnings and Precautions |
1. Dabigatran is not to be used by patients with severe kidney damage (CrCl<30ml/min). 2. Patients with high bleeding risk should also not use Dabigatran. 3. Patients must be tested and monitored for signs of lack of bleeding or anemia; if there is severe bleeding, cease use of Dabigatran and identify the bleeding area. 4. Dabigatran is not suitable for patients with significant manifestations of rheumatic valvar heart disease or patients with artificial heart valves. |
| Description | Dabigatran etexilate is an orally administered pro-drug of dabigatran, which is a direct inhibitor of thrombin and a potent anticoagulant. The serine protease thrombin is the final mediator in the coagulation cascade that leads to the production of fibrin, the main protein component of blood clots. Thrombin is also a potent activator of platelets. Consequently, thrombin inhibitors have found utility as anticoagulants in treating arterial and venous thrombosis. Warfarin, although orally available, has a narrow therapeutic index and requires frequent monitoring and dosage adjustment. Low-molecular-weight heparins provide better safety profile and less inter-patient variability; however, these agents are only available for parenteral administration. Direct thrombin inhibitors (DTIs) are a new class of anticoagulants that act by directly binding to thrombin at its catalytic or fibrinogen-binding sites, or both. Unlike the heparins, DTIs do not require the activation of secondary factors such as antithrombin to derive their activity, which makes their action more predictable. In addition, their ability to inhibit both free and clot-bound thrombin predisposes them for enhanced anticoagulation effect. |
| Originator | Boehringer Ingelheim (Germany) |
| Uses | BIBR-1048 (Dabigatran) is an anticoagulant from the class of the direct thrombin inhibitors. It is being studied for various clinical indications and in many cases it offers an alternative to warfarin as the preferred orally administered blood thinner sin |
| Definition | ChEBI: An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amino group of thyl N-pyridin-2-yl-beta-alaninate. A prodrug for dabigatran, a thrombin inhibitor and anticoagulant which is used for the prevention of stroke and systemic embolism. |
| Brand name | Pradaxa |
| Chemical Synthesis | The chemical synthesis of dabigatran etexilate starts with the acylation of ethyl 3-(2-pyridylamino)propionate with 4-(methylamino)-3-nitrobenzoyl chloride to produce the corresponding amide. Subsequent reduction of the nitro group by catalytic hydrogenation, and cyclization of the resultant phenylenediamine with N-(4-cyanophenyl)glycine leads to a benzimidazole intermediate. The cyano group is then transformed into an amidine by employing the Pinner reaction. Finally, acylation of the amidino group with hexyl chloroformate gives rise to dabigatran etexilate. |
Details
Changzhou Xuanming Chemical Co., Ltd. is dedicated to the technology development, manufacturing, import and export chemicals, which are specialized in pharmaceutical intermediates, pesticide intermediate, industry of fine chemicals and custom synthesis. Now, we enjoy good reputation among customers and take favorable market share in domestic and at abroad.
Changzhou Xuanming Chemical CO., LTD is located in Northern Jiangshu Industry Park, we have modern manufacture bases and some laboratories, which can supply the key intermediate for your projects, and short your synthesis scheme and supply you a reference compound for bioassay or a high purity analytical standard. We have been abided by “treat technology as first, quality as basis, customers as God, and be honest and sincere”. It is our final aim to provide environmental and high technological products and meet customers’ requirements according to keep effors on developing new chemical fields.
Changzhou Xuanming Chemical CO., LTD promises to help you with heart and soul.
